Search research articles
Contact Us
Filters
Showing results (1-10 of 129) with videos related to
Page
of 13
Sort By:
The Oncologist
|
November 3, 2005
Bisphosphonate treatment recommendations for oncologists
Roger von Moos
Journal of Clinical Medicine
|
August 4, 2015
Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?
Roger von Moos, Ian Haynes
European Journal of Dermatology : EJD
|
February 14, 2009
"Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome"
Roger Von Moos, Richard Cathomas
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
February 7, 2012
Denosumab: first data and ongoing studies on the prevention of bone metastases
Roger von Moos, Tomas Skacel
Revue Medicale Suisse
|
December 18, 2015
[Is prescription of a therapy costing 150,000 CHF reasonable?]
Solange Peters, Roger von Moos, Beat Thurlimann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2006
CASE 3. Red eye in Sjogren's syndrome due to underlying mucosa-associated lymphoid tissue lymphoma
Roger von Moos, Thomas Ruhstaller, Christian Fretz
The New England Journal of Medicine
|
November 7, 2007
Drug-induced immune thrombocytopenia
Richard Cathomas, Aron Goldhirsch, Roger von Moos
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 3, 2009
Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communication
Roger von Moos, Reto Schaffner, Richard Cathomas, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 7, 2008
Metastatic bone pain: treatment options with an emphasis on bisphosphonates
Roger von Moos, Florian Strasser, Silke Gillessen, et al.
Swiss Medical Weekly
|
March 20, 2003
Thalidomide: from tragedy to promise
Roger von Moos, Rahel Stolz, Thomas Cerny, et al.
Page
of 13
Search research articles
Search
Showing results (1-10 of 129) with videos related to
Sort By:
Page
of 13
The Oncologist
|
November 3, 2005
Bisphosphonate treatment recommendations for oncologists
Roger von Moos
Journal of Clinical Medicine
|
August 4, 2015
Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?
Roger von Moos, Ian Haynes
European Journal of Dermatology : EJD
|
February 14, 2009
"Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome"
Roger Von Moos, Richard Cathomas
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
February 7, 2012
Denosumab: first data and ongoing studies on the prevention of bone metastases
Roger von Moos, Tomas Skacel
Revue Medicale Suisse
|
December 18, 2015
[Is prescription of a therapy costing 150,000 CHF reasonable?]
Solange Peters, Roger von Moos, Beat Thurlimann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2006
CASE 3. Red eye in Sjogren's syndrome due to underlying mucosa-associated lymphoid tissue lymphoma
Roger von Moos, Thomas Ruhstaller, Christian Fretz
The New England Journal of Medicine
|
November 7, 2007
Drug-induced immune thrombocytopenia
Richard Cathomas, Aron Goldhirsch, Roger von Moos
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 3, 2009
Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communication
Roger von Moos, Reto Schaffner, Richard Cathomas, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 7, 2008
Metastatic bone pain: treatment options with an emphasis on bisphosphonates
Roger von Moos, Florian Strasser, Silke Gillessen, et al.
Swiss Medical Weekly
|
March 20, 2003
Thalidomide: from tragedy to promise
Roger von Moos, Rahel Stolz, Thomas Cerny, et al.
Page
of 13